{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of CI were not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"4.6","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG002","lowerLimit":"2.2","upperLimit":"NA","value":"5.0"},{"comment":"Lower and upper limit of 95% CI could not be calculated for 1 participant.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"DOR was defined as time from first objective response (OR) to disease progression (PD) or death. OR is defined in OM#25 (Substudy B), 28 (Substudy C), and 29 (Substudy D). PD: score 4 (uptake moderately \\>liver) or 5 (uptake markedly\\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"OG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"The Modified Intent-to-Treat Analysis Set consisted of all participants enrolled and treated with pivotal dose of brexucabtagene autoleucel, with measurable disease at baseline (or post-bridging therapy, if applicable). Participants in substudies B, C and D, in the Modified Intent-to-Treat Analysis Set with objective response were analyzed. Substudy A was withdrawn, therefore no participants were enrolled in it. Hence, data is not available.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"All Substudies (Substudies A, B, C and D): Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}